Clinical Trials Sponsored by Amager Hospital

Total 101765 results

ArmaGen, Inc

Completed

Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

Mucopolysaccharidosis I

Brazil
Amakem, NV

Completed

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma | Eye Disease

United States
ArmaGen, Inc

Completed

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

Mucopolysaccharidosis I

Brazil
ArmaGen, Inc

Completed

Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

Mucopolysaccharidosis I
Revimmune
University Hospital, Limoges; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)

COVID-19 | Lymphocytopenia

France
ArmaGen, Inc

Completed

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

Mucopolysaccharidosis I

United States
ArmaGen, Inc

Completed

Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome

Mucopolysaccharidosis II

United States, Germany, Philippines
Amakem, NV

Completed

A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects

Ocular Hypertension | Glaucoma | Eye Disease

United Kingdom
Amakem, NV

Completed

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

Ocular Hypertension | Glaucoma | Eye Disease

United States
Massachusetts General Hospital
Brigham and Women's Hospital; Amgen

Completed

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
University Hospital, Ghent
Amgen; EffRx Pharmaceuticals

Completed

The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover

Erosive Osteoarthritis

Belgium
Amgen

Not yet recruiting

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Asthma
Amgen

Not yet recruiting

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

Osteoporosis
Amgen

Not yet recruiting

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Amgen

Recruiting

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Major Cardiovascular Event | Established Atherosclerotic Cardiovascular Disease

China
Amgen

Recruiting

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease

United States
Amgen

Recruiting

Aimovig Pregnancy Exposure Registry

Migraine

United States
Amgen

Recruiting

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (ESSENCE)

Plaque Psoriasis

China
Amgen

Recruiting

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Amgen

Recruiting

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Osteogenesis Imperfecta

Turkey, Hungary, Germany, Switzerland, Spain, Japan, France, Belgium, Poland, Australia, Austria, Slovakia, United States, Canada
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Netherlands, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico
Amgen

Recruiting

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Spain, Australia, Germany, France, Japan
Amgen

Recruiting

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

Small Cell Lung Cancer (SCLC)

China, United States, Australia, Netherlands, Taiwan, Spain, Canada, Korea, Republic of, Turkey, Israel, Austria, Japan, France, United Kingdom, Germany, Belgium, Denmark, Czechia, Switzerland, Italy, Hungary, Ireland, Argentina, Brazil, Malays... and more
Amgen

Recruiting

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Atopic Dermatitis

United States, Korea, Republic of, Taiwan, Spain, Croatia, China, Greece, Belgium, Thailand, Puerto Rico, Hungary, Poland, Germany, Brazil, Italy, Japan, Canada, France, Romania, Chile
Amgen

Recruiting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Idiopathic Inflammatory Myositis

Mexico, United States, Spain, Australia, Italy, United Kingdom, Czechia, Brazil, Germany
Amgen

Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

Atopic Dermatitis

Korea, Republic of, Australia, United States, United Kingdom, Hong Kong, Turkey, Brazil, Argentina, Canada
Amgen

Recruiting

Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus (RECAST DLE)

Discoid Lupus Erythematosus

United States, Germany, Canada, France, Greece, Denmark, Brazil, Bulgaria, Czechia, Argentina, Poland
Amgen

Recruiting

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Taiwan, Switzerland, Spain, Canada, Israel, Germany, France, Belgium, Australia, Japan, Italy, Denmark
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Italy, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Finland and more
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103)

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of, Taiwan, Japan, Singapore, United States
Amgen

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)

Active Juvenile Psoriatic Arthritis

Spain, Turkey, Belgium, France, Greece, Italy, United Kingdom, Austria, Germany, Netherlands, Poland, Romania, Lithuania, South Africa, Portugal
Amgen

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Amgen

Completed

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Gout | Chronic Uncontrolled Gout | Uncontrolled Gout

United States
Amgen

Active, not recruiting

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis

Japan
Amgen

Terminated

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Lupus Nephritis

Spain, Brazil, Taiwan, Thailand, Croatia, Serbia, United States, Malaysia, Poland, Philippines, Argentina, Israel
Amgen

Active, not recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Australia, Japan, Canada, Taiwan, Netherlands, Italy, Chile, Greece, Mexico, Germany, France, Argentina, Poland, Turkey, South Africa, United Kingdom
Amgen

Terminated

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study (RECAST SLE OLE)

Systemic Lupus Erythematosus

United States, Spain, Serbia, Mexico, Poland, Greece, Argentina, India, Taiwan
Amgen

Completed

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Higher Risk Myelodysplastic Syndrome

United States
Amgen

Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

Relapsed or Refractory Multiple Myeloma

France, Czechia, Sweden, United States, Greece, Spain, Finland, Romania, Germany, Japan, Netherlands, Turkey, Austria, Bulgaria, Lithuania, Russian Federation, Slovakia
Amgen

Withdrawn

A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants

Healthy Participants
Amgen

Completed

AMG 334 20160172 Pediatric Migraine PK Study.

Migraine

United States
Amgen

Completed

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

Migraine Headache

United States, Austria, Australia, Czechia, Finland, France, Hungary, Italy, Poland, Portugal, Spain, United Kingdom
Amgen

Active, not recruiting

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis

United States, Canada
Amgen

Completed

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Systemic Lupus Erythematosus

United States
Amgen

No longer available

Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (RIALTO)

Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia

United States, Italy, Germany, Austria, France, Switzerland, United Kingdom
Amgen

Active, not recruiting

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

Relapsed/Refractory Small Cell Lung Cancer

United States, Belgium, Italy, Spain, Portugal, Austria, Greece, Korea, Republic of, Denmark, Netherlands, Germany, France, Taiwan, Japan, United Kingdom, Poland, Switzerland, Singapore
Amgen

Completed

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE)

United States, Korea, Republic of, Australia, Spain, Hungary, Bulgaria, Italy, Mexico, Germany, Japan, France, Greece, Czechia, Argentina, Portugal, Poland, Russian Federation, Hong Kong, Canada
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Dyslipidemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Czechia, Hungary, Taiwan, Colombia, Poland, Russian Federation, Switzerland, Korea, Republic of, Mexico, ... and more
Amgen

Completed

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Advanced Non CNS Tumors

United States, Belgium, Spain, France, Canada, Italy, Switzerland

Clinical Trials Sponsored by Amager Hospital

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations